[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qian Chu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,65,94,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100597214","phase-2-durvalumab-as-consolidation-for-patients-ls-sclc-100597214",false,"NCT07055581","Durvalumab as Consolidation for Patients LS-SCLC","A Phase II Study of Durvalumab Combined With EP Prior to Chemoradiotherapy and Followed by Durvalumab as Consolidation for Patients With Limited-stage Small-cell Lung Cancer (CONCUR Study)","Inclusion Criteria:\n\n* 1.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* 2.Histologically or cytologically confirmed small cell lung cancer\n* 3.Limited-stage, defined as stage I-III SCLC (T any, N any, M0). Patients who are Stage I or II must be medically inoperable as determined by investigator.\n* 4.Age \\> 18 years.\n* 5.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* 6.Adequate normal organ and marrow function.\n* 7.Must have a life expectancy of at least 12 week.\n* 8.At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion (TL) at baseline. Tumor assessment by computed tomography (CT) scan or magnetic resonance imaging (MRI) must be performed within 28 days prior to enrollment.\n\nExclusion Criteria:\n\n* 1.Patients with extensive disease small-cell lung cancer.\n* 2.Patients who previously received radiotherapy to the thorax or chemotherapy for small cell lung cancer.\n* 3.Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology. Patients with mixed histology tumors with predominant SCLC histology are allowed.\n* 4.Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values.\n* 5.Any concurrent chemotherapy other than study treatment, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n* 6.History of allogenic organ transplantation.\n* 7.Active or prior documented autoimmune or inflammatory disorders.\n* 8.Uncontrolled intercurrent illness.\n* 9.History of leptomeningeal carcinomatosis.\n* 10.Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)\n* 11.History of active primary immunodeficiency\n* 12.Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of antiHBc and absence of HBsAg) and with undetectable HBV DNA (\\\u003C 10 IU\u002Fml or under the limit of detection per local lab standard) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* 13.Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.\n* 14.Prior treatment in a previous durvalumab clinical study.\n* 15.Known allergy or hypersensitivity to IP or any excipient.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Small-Cell Lung Cancer (SCLC) accounts for 10% to 15% of new lung cancers and is a highly aggressive neuroendocrine tumor. In the past 30 years, the treatment of SCLC has made very limited progress, and basically made breakthroughs in radiotherapy and chemotherapy. With the advent of the immune era, immunotherapy has achieved initial results in the treatment of SCLC. Approximately one-third of patients with small cell lung cancer are in limited-stage (LS-SCLC) disease at first diagnosis. Except for a very small number of patients with T1-2N0 who can be treated with surgery or stereotactic radiation therapy (SBRT), the standard treatment for the rest of the patients with LS-SCLC is concurrent chemoradiotherapy. The ORR of platinum-combined etoposide regimen combined with thoracic radiotherapy in LS-SCLC can reach 70% to 90%, and the median OS is 16-24 months, which significantly improves the survival of patients. Although many measures have been taken in the treatment of LS-SCLC, only 20% of LS-SCLC can be cured, and most patients have relapse and metastasis after treatment. This study is a single arm phase II preliminary pilot study, aim to assess the efficacy and safety of durvalumab combined with EP prior to CRT and followed by durvalumab consolidation therapy for LS-SCLC.",[26],"Small Cell Lung Cancer Limited Stage",[28],"small cell lung cancer","RECRUITING","2026-03-26",{"date":32,"type":33},"2026-03-27","ACTUAL",{"date":35,"type":33},"2026-02-24",{"date":37,"type":20},"2029-07-31",{"name":39,"class":40},"Qian Chu","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100622834","prediction-of-outcome-to-neoadjuvant-therapy-in-non-small-cell-lung-cancernsclc-100622834","NCT07388771","Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）","A Study on Multimodal Data Prediction of Outcome to Neoadjuvant Therapy in NSCLC","Inclusion Criteria:\n\n1. pathologically diagnosed non-small cell lung cancer\n2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection\n\nExclusion Criteria:\n\n1. recurrent or metastatic lung cancer;\n2. patients with other primary tumors",{"count":50,"type":20},500,"6 Months","OBSERVATIONAL","This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC.\n\nThe core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?",[55,56],"NSCLC","Neoadjuvant Therapy","2026-03-18",{"date":59,"type":33},"2026-03-19",{"date":61,"type":33},"2025-12-01",{"date":63,"type":20},"2026-10",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100603065","symptoms-burden-in-lung-cancer-patients-undergoing-definitive-chemoradiotherapy-insights-from-electronic-patient-reported-outcomes-100603065","NCT07131670","Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","ePRO-LC-CRT","Inclusion Criteria:\n\n* Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC\n* Age ≥ 18 years\n* Receiving definitive chemoradiotherapy\n* Able and willing to complete electronic questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe comorbidities (heart, liver, kidney)\n* Psychiatric illness or cognitive impairment\n* Prior chest or mediastinal radiotherapy",{"count":19,"type":20},"This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.",[76,77,78],"Lung Cancer","Chemoradiotherapy","Patient-Reported Outcomes (PRO)",[80,81,82,83,76,84],"Symptom Burden","Symptom Clusters","Electronic Patient-Reported Outcomes","MDASI-LC","EQ-5D","2025-08-12",{"date":87,"type":33},"2025-08-20",{"date":89,"type":33},"2024-06-01",{"date":91,"type":20},"2026-03-31",{"name":39,"class":40},1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100430695","phase-2-camrelizumab-plus-famitinib-as-treatment-in-patient-with-advanced-or-metastatic-pulmonary-sarcomatoid-carcinoma-100430695","NCT04888429","Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma","Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma：A Multi-center, Single-arm Study","CAPSTONE","Inclusion Criteria:\n\n* Patients with histologically stage IIIB, IIIC, IV Pulmonary Sarcomatoid Carcinoma according to WHO criteria or diagnosed with non-small cell lung cancer with sarcomatoid carcinoma component (sarcomatoid component tumour cells can be spindle cells, and\u002For giant cells and\u002For heterogenous sarcomatous differentiation including rhabdomyosarcoma, chondrosarcoma, etc.) ；\n* Has no prior systemic therapy; (chemotherapy and\u002For radiotherapy is allowed as part of neoadjuvant\u002Fadjuvant therapy. Patients who have had recurrence or metastasis for more than 6 months from the end of neoadjuvant\u002Fadjuvant treatment would be enrolled ) ；\n* Patients must have at least one measurable lesion according to RECIST 1.1 ；\n* ECOG score 0-1 ；\n* Agree to provide tumour tissue samples for biomarker exploration (including but not limited to PD-L1 IHC or NGS testing) ；\n* Life expectancy more than 3 months;\n* Has adequate organ function；\n\nExclusion Criteria:\n\n* Imaging (CT or MRI) showed tumor invasion of major vessels. hemoptysis ≥ 2.5 mL within 1 month before the first dose;\n* Patients with EGFR-sensitive mutation (19Exondel\u002FL858R), ALK, ROS1 gene rearrangement or fusion, BRAFV600E mutation, MET gene exon 14 skipping mutation;\n* Patients with active bleeding or bleeding tendency ；\n* With hypertension that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure ≤ 140 mmHg\u002Fdiastolic blood pressure ≤ 90 mmHg)；\n* Urine protein ≥ (+ +), and 24-hour urine protein ≥ 1.0g;\n* Presence of thrombotic disorder requiring anticoagulant therapy with warfarin or heparin, or requiring antiplatelet therapy (aspirin ≥ 300 mg\u002Fday or clopidogrel ≥ 75 mg\u002Fday) ；\n* Has multiple factors affecting the absorption of oral drugs, such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction\n* Has active central nervous system (CNS) metastases confirmed by CT or MRI\n* Subjects diagnosed immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy of non-related tumor within 7 days before the first dose; allowed physiological dose of glucocorticoid (≤10 mg\u002Fday Prednisone or equivalent);\n* Has active hepatitis B ;\n* Has severe infections within 4 weeks of the first dose of study treatment ;\n* Women who are pregnant or lactating ;\n* With grade II or above myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (QTc interval ≥ 450 ms for males and QTc interval ≥ 470 ms for females). Subjects with grade III-IV cardiac insufficiency or with left ventricular ejection fraction (LVEF) less than 50% according to NYHA criteria;\n* Has known history of Human Immunodeficiency Virus (HIV)；\n* Has known allergy to Camrelizumab, or famitinib or any of accessories ;","75 Years",{"count":104,"type":20},28,[23],"This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.",[108],"Sarcomatoid Carcinoma of Lung",[108,110,111],"Camrelizumab","Famitinib","2024-09-26",{"date":114,"type":33},"2024-10-01",{"date":116,"type":33},"2021-07-19",{"date":118,"type":20},"2025-06-30",{"name":39,"class":40},8,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":93},"100516179","phase-2-cadonilimab-ak104-plus-chemotherapy-as-first-line-treatment-in-non-squamous-non-small-cell-lung-cancer-nsclc-patients-with-programmed-cell-death-ligand-1-pd-l1-negative-100516179","NCT06001151","Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative","Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative：A Multi-center, Single-arm, Phase II Study","ACHELOUS","Inclusion Criteria:\n\n* Patients with histologically\u002Fcytologically stage IIIB, IIIC, IV non-squamous Non-Small Cell Lung Cancer (NSCLC)\n* PD-L1 TPS\\\u003C1%\n* Life expectancy more than 3 months\n* Without EGFR-sensitive mutation (19Exon del\u002F21Exon L858R), ALK, ROS1 gene rearrangement or fusion\n* Has no prior systemic therapy; (chemotherapy and\u002For radiotherapy is allowed as part of neoadjuvant\u002Fadjuvant therapy. Patients who have had recurrence or metastasis for more than 6 months from the end of neoadjuvant\u002Fadjuvant treatment would be enrolled)\n* ECOG score 0-1\n* Patients must have at least one measurable lesion according to RECIST 1.1\n* Has adequate organ function\n* Agree to provide tumour tissue samples for biomarker exploration (including but not limited to PD-L1 IHC or NGS testing)\n* Voluntarily sign a written informed consent form\n\nExclusion Criteria:\n\n* Histological examination with Small Cell Lung Cancer or squamous Non-Small Cell Lung Cancer\n* With active central nervous system (CNS) metastases confirmed by CT or MRI\n* With other malignancy within 3 years before enrollment\n* With severe infections within 4 weeks of the first dose of study treatment\n* Women who are pregnant or lactating\n* History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia requiring hormone therapy\n* History of myocarditis, cardiomyopathy, and malignant arrhythmia\n* Tumor compresses important surrounding organs (such as the esophagus) with accompanying symptoms, compressing the superior vena cava or invading the mediastinal vessels, heart, etc.\n* Risk of bleeding, major hemoptysis, or with history of coagulation dysfunction\n* Active autoimmune diseases that require systematic treatment within 2 years before enrollment\n* History of Human Immunodeficiency Virus (HIV)\n* With active hepatitis B infection\n* With uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage",{"count":130,"type":20},49,[23],"This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1\u002FCTLA-4 bi-specific antibody.",[134],"Carcinoma, Non-Small-Cell Lung",[136,137,138],"non-squamous Non-Small Cell Lung Cancer","Programmed Cell Death Ligand 1","cadonilimab","2023-08-18",{"date":141,"type":33},"2023-08-21",{"date":143,"type":33},"2023-08-07",{"date":145,"type":20},"2027-08-31",{"name":39,"class":40},""]